AMO pulls lens care solution

Article

AMO is voluntarily recalling its Complete MoisturePlus contact lens solutions after receiving data from the US Centers for Disease Control and Prevention (CDC) linking the solution with an increase in the occurrence of the eye infection, acanthamoeba keratitis.

AMO is voluntarily recalling its Complete MoisturePlus contact lens solutions after receiving data from the US Centers for Disease Control and Prevention (CDC) linking the solution with an increase in the occurrence of the eye infection, acanthamoeba keratitis (AK).

CDC data from interviews with 46 patients who developed AK, found that 39 were soft contact lens wearers and 21 of these reported using Complete MoisturePlus products. The CDC has estimated the risk of developing AK is at least seven times greater for those using the AMO solution than for those using alternative solutions. However, there is no evidence to suggest that the recall is related to product contamination and does not apply to any other AMO contact lens care products.

Contact lens wearers are advised to see their doctor if they have any of the following symptoms: eye pain, redness, blurred vision, sensitivity to light, the sensation of something in the eye or excessive tearing.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.